Physicians at the Heart Hospital of Austin, enrolled and successfully treated the first patient in the Roadster study, a global, multicenter clinical trial evaluating the safety and efficacy of the Silk Road System for the treatment of carotid artery disease. Mazin I. Foteh, M.D., a vascular surgeon and principal investigator for the trial, performed the first procedure.

A telestroke service increases the rate of effective tissue plasminogen activator (tPA) therapy for patients with acute ischemic stroke treated at community hospitals, according to a report in the October issue of Neurosurgery. 

Cath lab IMV market report

Purchasing activity for cardiac catheterization labs in the United States appears to be growing as more healthcare facilities look to replace aging equipment, according to a new report by IMV Medical Information Division. The census-based report finds that both patient volume and installed base are rising as the market recovers from a recent slowdown.

According to the KLAS report Clinical Market Share 2013: More than Meaningful Use, Cerner Corporation and Epic Systems combined captured more than three-fourths of new large-hospital electronic medical records (EMR) contracts, while the other vendors struggled to keep pace.

Immediate U.S. government furloughs affecting virtually all National Science Foundation (NSF) employees and three-fourths of those at the National Institutes of Health (NIH) could impact U.S. competitiveness, American Association for the Advancement of Science (AAAS) warned.

EndoCross, Ltd. announced today that it has already enrolled one-third of the patients planned for the first-in-human study of its Enabler-C Catheter System for Crossing Coronary Chronic Total Occlusions (“Enabler 3C” study). The Enabler 3C clinical study is taking place at the Institut Cardiovasculaire Paris-Sud under principal investigator Dr. Yves Louvard.

Delivering the precision, clinical sensitivity and clinical specificity necessary to assist physicians with the diagnosis of myocardial infarction (MI), Beckman Coulter Inc. announced the U.S. Food and Drug Administration (FDA) clearance of its new Access AccuTnI+3 troponin I assay for use on the UniCel DxI series of immunoassay systems.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now